NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Kadimastem Ltd (TA: KDST)
KDST Technical Analysis
5
As on 1st Apr 2025 KDST STOCK Price closed @ 2525.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 300.66 & Strong Buy for SHORT-TERM with Stoploss of 59.14 we also expect STOCK to react on Following IMPORTANT LEVELS. |
KDSTSTOCK Price
Open | 2751.00 | Change | Price | % |
High | 2770.00 | 1 Day | -249.00 | -8.98 |
Low | 2316.00 | 1 Week | 678.00 | 36.71 |
Close | 2525.00 | 1 Month | 585.00 | 30.15 |
Volume | 7485 | 1 Year | 2467.30 | 4276.08 |
52 Week High 2147.00 | 52 Week Low 50.00 |
TA Israel Most Active Stocks
TA125 | 2008.05 | 1.06% |
DSCT | 2607.00 | 1.24% |
BEZQ | 540.00 | -1.21% |
ORL | 90.00 | 1.93% |
ELAL | 1139.00 | 1.24% |
BLRX | 1.90 | 0.00% |
LUMI | 4998.00 | 0.32% |
POLI | 5008.00 | 0.00% |
RATI-L | 392.30 | 5.80% |
TDGN-L | 171.50 | 17.55% |
TA Israel Top Gainers Stocks
TA Israel Top Losers Stocks
KDST Daily Charts |
KDST Intraday Charts |
Whats New @ Bazaartrend |
KDST Free Analysis |
|
KDST Important Levels Intraday
RESISTANCE | 3399.86 |
RESISTANCE | 3119.29 |
RESISTANCE | 2945.86 |
RESISTANCE | 2772.43 |
SUPPORT | 2277.57 |
SUPPORT | 2104.14 |
SUPPORT | 1930.71 |
SUPPORT | 1650.14 |
KDST Forecast April 2025
4th UP Forecast | 2565.27 |
3rd UP Forecast | 2552.36 |
2nd UP Forecast | 2544.37 |
1st UP Forecast | 2536.39 |
1st DOWN Forecast | 2513.61 |
2nd DOWN Forecast | 2505.63 |
3rd DOWN Forecast | 2497.64 |
4th DOWN Forecast | 2484.73 |
KDST Weekly Forecast
4th UP Forecast | 2544.27 |
3rd UP Forecast | 2538.09 |
2nd UP Forecast | 2534.27 |
1st UP Forecast | 2530.45 |
1st DOWN Forecast | 2519.55 |
2nd DOWN Forecast | 2515.73 |
3rd DOWN Forecast | 2511.91 |
4th DOWN Forecast | 2505.73 |
KDST Forecast2025
4th UP Forecast | 7804.02 |
3rd UP Forecast | 6111.01 |
2nd UP Forecast | 5064.52 |
1st UP Forecast | 4018.03 |
1st DOWN Forecast | 1031.97 |
2nd DOWN Forecast | -14.52 |
3rd DOWN Forecast | -1061.01 |
4th DOWN Forecast | -2754.02 |
Kadimastem Ltd ( TA Israel Symbol : KDST )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
KDST Other Details
Segment | EQ | |
Market Capital | 12275118080.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
KDST Address
![]() |
KDST Latest News
KDST Business Profile
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel. Address: Pinchas Sapir 7, Ness Ziona, Israel, 74140
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service